Skip to main content
GHRP-6
All ingredients
Ingredients/Peptide/GHRP-6

GHRP-6.

Strength pending.The research strength is not set yet.

GHRP-6 is a synthetic hexapeptide agonist at the ghrelin receptor. It releases a pulse of growth hormone from the pituitary and stimulates appetite through hypothalamic pathways.

100 to 200mcgDaily amount1,093Studies read

Reviewed March 2026

GHPeptide
GHRP-6IngredientMD
Category
Peptide

What GHRP-6 is, and what it does.

Does it work
It suits research and clinically supervised settings looking at the growth hormone axis. Gut proteases degrade it, so it isn't something that works as an oral supplement ingredient.
How much to take
No oral amount applies, since it's degraded in the gut. On record are 100 to 200mcg a day as a maintenance band and 300mcg as a research condition, both under clinical supervision.
Time to feel it
Growth hormone climbs within about half an hour of a dose and settles the same day. That is a blood measurement rather than something you sense.
The first dose
Growth hormone climbs within about half an hour and settles the same day, visible on a blood draw. Marked hunger, and sometimes warmth or flushing, is what people report.
With regular use
With repeated exposure the receptor desensitises, so each pulse is smaller than the first. Across 1,093 Europe PMC records, long-term human outcome data stays thin.
How well tolerated
A research peptide rather than a supplement, and one for clinical supervision only. Agonism here also raises prolactin and cortisol, so a whole axis moves, not one hormone.
How it feels
Marked hunger is the consistent report, because this receptor also carries normal appetite signalling. Some people describe warmth or flushing soon after a dose.
The overlooked benefit
It isn't selective. The same receptor push that lifts growth hormone also nudges prolactin and cortisol, so what you measure afterwards is a whole axis, not one hormone.

100 to 200mcg a day is where GHRP-6 works.

How much to take a dayLimited data
100 to 200mcg
Daily maintenanceThe everyday amount, and where most daily supplements sit. This is the one you take month after month.
300mcgClinical territory. Trials run high on purpose, for a set number of weeks, against one measured outcome. Impressive to hit, and not what a daily product is for.
Above 500mcgPast what the research covers. More capsules rather than more effect.
MORE EFFECT ↑0200mcg300mcg plateauDAILY DOSE →
The shaded band is where the dosing trials landed.

Source: Bowers, Endocr Rev, 1998

The proof, claim by claim.

These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.

GHRP-6 has emerging evidence. Based on 1093+ studies.

  • Growth hormone release from the pituitaryRandomised trial
  • Prolactin and cortisol rise alongside growth hormoneRandomised trial
  • Appetite stimulation through hypothalamic pathwaysAnimal study
  • Receptor desensitisation with sustained exposureNarrative review
PubMedCochraneClinicalTrials.govNIH ODSSUPP.AI1,093 studies readLabs test. IngredientMD verifies.PubMedCochraneClinicalTrials.govNIH ODSSUPP.AI1,093 studies readLabs test. IngredientMD verifies.

Questions people ask about GHRP-6.

When should I take it?
Timing matters less than consistency. Pick a time that works for you and take it daily.
Can I take it with other supplements?
Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
Any side effects to watch for?
Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
Who benefits most from this?
Honestly, most people would benefit more from the basics. But if you've got a specific reason to try it, the risk is generally low.
Pairs well with11 on file

Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.

GHRP-6 + Ipamorelinsame receptor, shared site

GHRP-6 and ipamorelin are both ghrelin receptor agonists competing for one binding site. Ipamorelin is more selective, while GHRP-6 carries the strongest appetite signal of the class.

GHRP-6 + Hexarelinsame receptor, shared site

Both are hexapeptide ghrelin receptor agonists, so they occupy the same site rather than complementing each other. Doubling up mainly amplifies the class effects on cortisol and prolactin.

GHRP-6 + Tesamorelincomplementary receptors on one axis

Tesamorelin signals through the GHRH receptor while GHRP-6 signals through the ghrelin receptor and eases somatostatin restraint. Two different receptors on the same axis is the reason this class pairing is used at all.

GHRP-6 + L-Argininelowers the opposing hormone

Arginine lowers somatostatin tone at the pituitary, and ghrelin receptor agonists lean on the same brake release. Their mechanisms partly overlap rather than being fully separate.

GHRP-6 + Glucoseblunts the same pulse

A glucose and insulin rise increases somatostatin and suppresses the pituitary reply to a secretagogue. Timing around carbohydrate is the main practical determinant of the size of the pulse.

GHRP-6 + CJC-1295A long-acting growth hormone-releasing hormone analogue, so the same dual-receptor logic as with other GHRH-receptor agonists.

Extending GHRH-receptor drive alongside secretagogue-receptor drive changes the shape of pulsatile growth hormone release rather than simply adding two peaks. What is measured in such work is hormone concentration, a marker. The pairing is a research and clinical-pharmacology construct, and none of it establishes a health outcome.

GHRP-6 + MK-677 ibutamorenAn orally active non-peptide agonist at the same growth hormone secretagogue receptor, so the two compete for one receptor rather than complement each other.

Both compounds bind GHS-R1a. Occupancy by one reduces the sites available to the other, and the receptor also desensitises with sustained agonism, so stacking two agonists does not scale the response. This is receptor pharmacology and it argues against, not for, combining them.

GHRP-6 + L-ornithineBasic amino acids have been studied for effects on growth hormone secretion, the same measured marker that secretagogue peptides raise.

Ornithine and arginine have been examined for modest effects on circulating growth hormone, possibly through reduced somatostatin tone. The effect sizes reported for amino acids are small next to a receptor agonist. Any combined row here describes a hormone marker and stays at Early confidence.

GHRP-6 + MCT oilA rise in circulating free fatty acids suppresses growth hormone release, an established inhibitory limb of the axis.

Free fatty acid elevation blunts both spontaneous and secretagogue-stimulated growth hormone secretion at the pituitary. A fat load taken close to a secretagogue therefore works against it, which is why endocrine testing is done fasted. This is a timing interaction described in classical endocrinology, and it points to separating the two.

GHRP-6 + GABAGABA has been studied for effects on circulating growth hormone, again as a hormone marker rather than an outcome.

Oral GABA has been reported to raise measured growth hormone acutely in small human studies, with unclear central versus peripheral mechanism. The measurement is a hormone level, and effect durability is unestablished. Regard any pairing claim as exploratory.

GHRP-6 + MelatoninGrowth hormone secretion is strongly sleep-entrained, and the largest natural pulses occur during slow-wave sleep.

Because the somatotropic axis is coupled to sleep architecture, anything that shifts sleep timing shifts the endogenous pulse pattern a secretagogue is layered onto. Melatonin acts on circadian timing rather than on the pituitary receptor. The interaction is on timing of a marker and has not been quantified for this combination.

Who should be cautious

Nothing specific on file for GHRP-6. Match the label to the daily amount above, and tell your doctor what you take.

Not medical advice. Show the label to your pharmacist.

What GHRP-6 actually does.

Established

GHRP-6 is a synthetic hexapeptide agonist at the growth hormone secretagogue receptor 1a, the same receptor the gut hormone ghrelin binds, and it acts on pituitary somatotrophs and on hypothalamic neurons.

Established

Its effect on growth hormone release depends on intact growth hormone-releasing hormone signalling and on reduced somatostatin tone, which is why the response varies with the time of day and with the phase of the endogenous pulse.

Established

GHS-R1a activation is not selective to growth hormone: agonism at this receptor also raises prolactin and adrenocorticotropic hormone with cortisol, and stimulates appetite through hypothalamic pathways.

Established

As an unmodified short peptide it is degraded by gastrointestinal proteases and cleared rapidly from plasma, so oral exposure is negligible and the compound is handled parenterally in research settings.

Getting GHRP-6 from food.

The whole-food sources on file. A supplement closes the gap, it does not replace dinner.

Varied diet

A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.

The forms it comes in.

GHRP-6 acetate, lyophilisedAcetate salt of the hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys amide, supplied freeze-dried for reconstitution.Fits Research and clinical-pharmacology use where a defined peptide mass is reconstituted immediately before use.Trade-off Requires cold-chain handling and aseptic reconstitution, and the peptide degrades in solution, so stability in solution is short compared with the dry powder.
GHRP-6 free basePeptide without an added counterion, hygroscopic and less commonly supplied.Fits Situations where any counterion would interfere with the intended measurement.Trade-off Hygroscopicity makes the solid harder to handle, and solid-state stability is shorter than for a salt form.
What the strongest studies found

The essence, in one line each.

  1. In healthy men, growth hormone-releasing peptides produced distinct pulsatile growth hormone responses, differing in size between the secretagogues tested.Randomised trial. Norman et al., 2013 (American journal of physiology. Regulatory, integrative and comparative physiology). PMID 23485864 ↗
  2. The ghrelin analogue GHRP-6 delivered in feed altered endocrine and immune response measures in the aquatic species studied; endpoints were hormone and immune markers in a non-human species.Animal study. Rodriguez-Viera et al., 2025 (Biology). PMID 40906090 ↗
  3. A hydrogel delivery format for GHRP-6 was evaluated in a laboratory animal model for effects on renal metabolic regulation; a preclinical delivery and metabolism study, not human evidence.Animal study. Zhao et al., 2025 (Journal of Nanobiotechnology). PMID 41327290 ↗
  4. Administration of the related secretagogue GHRP-2 with cysteamine changed growth performance measures and somatotropic axis hormone concentrations in the animals studied; the peptide tested is GHRP-2, not GHRP-6.Animal study. Hu et al., 2016 (PLoS One). PMID 26894743 ↗
  5. In postmenopausal women, oestradiol status altered how a growth hormone-releasing peptide interacted with GHRH and somatostatin in driving pituitary output; the endpoint is growth hormone secretion, a hormone marker.Randomised trial. Norman et al., 2014 (European Journal of Endocrinology). PMID 24114435 ↗
  6. Recovery of pulsatile growth hormone secretion after growth hormone-induced negative feedback differed by sex, sex-steroid milieu and which secretagogue was used; all endpoints are hormone secretion measures.Randomised trial. Veldhuis et al., 2011 (The Journal of Clinical Endocrinology and Metabolism). PMID 21613353 ↗
  7. A preclinical investigation of how pulsatile growth hormone secretion recovers from negative feedback under peptide drive; the authors describe the work as preclinical, so it grounds mechanism rather than a human effect.Animal study. Veldhuis et al., 2011 (American Journal of Physiology: Regulatory, Integrative and Comparative Physiology). PMID 21795635 ↗

These are the studies our verdict leans on, chosen from the 162 we read for GHRP-6. The full linked list is below.

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.